IRIS
AURIEMMA, RENATA SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.720
EU - Europa 774
AS - Asia 543
AF - Africa 25
SA - Sud America 2
Totale 3.064
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.686
SG - Singapore 277
CN - Cina 226
IT - Italia 222
SE - Svezia 138
NL - Olanda 88
FI - Finlandia 81
IE - Irlanda 69
DE - Germania 55
UA - Ucraina 52
CA - Canada 33
FR - Francia 27
GB - Regno Unito 26
CI - Costa d'Avorio 24
IN - India 15
IR - Iran 13
CZ - Repubblica Ceca 5
VN - Vietnam 4
ES - Italia 3
BE - Belgio 2
LK - Sri Lanka 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AT - Austria 1
BG - Bulgaria 1
BO - Bolivia 1
BR - Brasile 1
EG - Egitto 1
IQ - Iraq 1
PA - Panama 1
PK - Pakistan 1
RU - Federazione Russa 1
SI - Slovenia 1
TH - Thailandia 1
TW - Taiwan 1
Totale 3.064
Salva come PNG Salva come JPEG
Città #
Chandler 369
Singapore 215
Millbury 98
Amsterdam 88
Ashburn 86
Santa Clara 77
Naples 75
Princeton 72
Jacksonville 70
Nanjing 59
Wilmington 50
Beijing 42
Boston 39
Napoli 36
Ottawa 32
Woodbridge 32
Des Moines 27
Falls Church 21
Seattle 21
Hebei 19
Nanchang 16
Lawrence 14
Shenyang 14
Helsinki 13
Munich 13
Ann Arbor 12
Ardabil 11
Rome 11
Houston 10
Jiaxing 10
Changsha 9
Dublin 9
Kronberg 9
San Mateo 9
San Francisco 8
Norwalk 7
Augusta 6
Boardman 6
Dallas 5
Indiana 5
Brno 4
Dong Ket 4
Kunming 4
Siena 4
Tianjin 4
Altamura 3
Bologna 3
Castellammare di Stabia 3
Danvers 3
Lanzhou 3
Lappeenranta 3
Lucca 3
Madrid 3
Maiori 3
Marigliano 3
Monmouth Junction 3
New York 3
Pune 3
Redwood City 3
Shanghai 3
Springfield 3
Bacoli 2
Casalecchio Di Reno 2
Dearborn 2
Fairfield 2
Fiumicino 2
Fort Worth 2
Guangzhou 2
Hangzhou 2
Harbin 2
Kuliyapitiya 2
Livorno 2
Los Angeles 2
Magdeburg 2
Monza 2
Mumbai 2
Paris 2
Puning 2
Redmond 2
Slough 2
Stockholm 2
Taizhou 2
Tappahannock 2
Turin 2
Washington 2
Avellino 1
Bangalore 1
Benevento 1
Cairo 1
Caserta 1
Cava de' Tirreni 1
Cercola 1
Chicago 1
Cicciano 1
Clifton 1
Coronel Bicaco 1
Dongguan 1
Edinburgh 1
Fuzhou 1
Gent 1
Totale 1.856
Salva come PNG Salva come JPEG
Nome #
Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age 84
Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly 65
Adverse events associated with somatostatin analogs in acromegaly. 61
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients 60
A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients 59
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance 59
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group 57
The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. 53
The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients 51
Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly 51
Erratum to: The treatment with pasireotide in Cushing’s disease: effects of long–term treatment on tumor mass in the experience of a single center (Endocrine, (2015), 50, (725-740) DOI 10.1007/s12020-015-0557-2) 49
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. 48
Hypertension in acromegaly and in the normal population: prevalence and determinants 47
The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. 46
Cabergoline use for pituitary tumors and valvular disorders. 45
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma 44
Bisphenol A: An emerging threat to female fertility 44
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit 43
Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. 42
Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. 42
Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head-to-head study 41
Evaluation of the retinal nerve fibre layer and ganglion cell complex thickness in pituitary macroadenomas without chiasmal compression. 41
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities 41
Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. 40
Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-monthstudy. 40
Effects of initial therapy for five years with somatostatin analogs foracromegaly on growth hormone and insulin-like growth factor-I levels, tumorshrinkage, and cardiovascular disease: a prospective study. 40
Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. 40
An evaluation of patients with hyperprolactinemia: have dynamic tests had their day? 39
Cardiovascular disease in Cushing's syndrome: heart versus vasculature. 38
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting 38
Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. 37
Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. 36
Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study 36
Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study 36
Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma 36
Acromegaly and the cardiovascular system 35
Increased risk of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a three-year longitudinal study with phalangeal QUS measurements 35
Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas 34
Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients 34
New perspectives in the medical treatment of acromegaly 33
Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment 33
Fertility in Acromegaly: a single center experience on female patients during active disease and after disease remission 32
Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial 32
Glycometabolic control in Acromegalic patients with Diabetes: a study of the effects of different treatments for GH excess and for hyperglycaemia. 31
Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). 31
The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs 30
Effects of the metabolic syndrome (METS) on gonadal function and sperm parameters in acromegalic patients: a retrospective analisys 30
Effect of the acute administration of the Dopamine Agonist Cabergoline on glucose tolerance and Insuline Sensitivity in patient with obesity. 30
Acromegaly and changes in growth parameters: A focus on cardiovascular,metabolic, respiratory abnormalities, malignancies, and bone alterations 30
Mediterranean Diet: What Are the Consequences for Menopause? 29
Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. 29
Severe systemic complications of acromegaly 29
Effect of Cabergoline on Metabolism in Prolactinomas. 29
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly 29
The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. 28
TREATMENT WITH GROWTH HORMONE RECEPTOR ANTAGONIST IN ACROMEGALY: EFFECT ON CARDIAC ARRHYTHMIAS. 28
The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology 28
Erratum to: Pituitary tumors and pregnancy: The interplay between a pathologic condition and a physiologic status (Journal of Endocrinological Investigation (2014) 37, (99-112) DOI: 10.1007/s40618-013-0019-8) 27
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. 26
The Vaginal Microbiome: A Long Urogenital Colonization Throughout Woman Life 26
Impact of Somatostatin Analogs vs. Surgery on glucose metabolism in acromegaly: Results of a 5 years observational, open, prospective study 25
Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. 24
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly 24
Gli analoghi della somatostatina nell'inquadramento clinico della patologia ipofisaria 24
Medical consequences of acromegaly: what are the effects of biochemical control? 23
The role of somatostatin receptors in the medical treatment of acromegaly 23
Different effect of acute administration of the dopamine agonist cabergoline on glucose tolerance and insulin sensitivity in obese pateints in relation to GH status. 23
The safety of treatments for prolactinomas 23
Early Left Ventricular Diastolic Dysfunction in Females with Chronic Hyperprolactinemia: A Doppler Echocardiographic Study 22
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance 22
Cushing, acromegaly, GH deficiency and tendons 22
Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy 21
Somatostatin analogs in the clinical management of pituitary neoplasms 21
Second attempt to withdraw cabergoline in prolactinomas: a pilot study 21
Prevalence of the Metabolic Syndrome in moderately-severely obese subjects with and without Growth Hormone Deficiency. 21
Alendronate: New formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects 21
Hyperprolactinemia after menopause: Diagnosis and management 21
Glucose abnormalities associated to prolactin secreting pituitary adenomas 20
Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. 19
Pituitary carcinomas. 18
null 18
A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. 18
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas 18
Metabolic effects of prolactin 18
Treatment with GH receptor antagonist in acromegaly:effect on cardiac arrhythmias. 17
Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly 17
Dopamine Agonists: From the 1970s to Today 17
Circulating myomiRNAs as biomarkers in patients with Cushing's syndrome 16
Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor 16
Efficacy and tolerability of treatment with pegvisomant in acromegaly: An overview of literature 16
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms 16
Approach to the Patient with Prolactinoma 15
Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health 15
Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease 14
The effects of hyperprolactinemia and its control on metabolic diseases 14
Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study 13
Significant tumour shrinkage after 12 months of Lanreotide Autogel-120 mg treatment given first-line in acromegaly. 13
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia 13
Diabetes and obesity as independent risk factors for osteoporosis in postmenopausal women: A population study 12
The environment and male reproductive system: the potential role and underlying mechanisms of cadmium in testis cancer 11
Totale 3.132
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.952
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.952
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020128 0 0 0 0 17 7 0 0 11 8 46 39
2020/2021249 8 11 34 13 13 50 13 3 28 11 60 5
2021/2022579 10 0 0 3 16 81 12 19 85 35 115 203
2022/2023819 97 89 21 66 97 90 4 69 144 98 34 10
2023/2024512 22 87 60 55 26 41 13 61 9 10 76 52
2024/2025453 164 162 43 30 54 0 0 0 0 0 0 0
Totale 3.225